Biomarin Pharmaceutical (BMRN) Cash from Operations Growth (3y) (2012 - 2026)
Biomarin Pharmaceutical (BMRN) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
37.40% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
20.11% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
16.64% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
70.82% |
| Date | Value |
|---|
| Mar 31, 2026 |
70.82% |
| Dec 31, 2025 |
144.88% |
| Sep 30, 2025 |
32.55% |
| Jun 30, 2025 |
48.81% |
| Mar 31, 2025 |
80.07% |
| Dec 31, 2024 |
155.11% |
| Sep 30, 2024 |
31.65% |
| Jun 30, 2024 |
12.78% |
| Mar 31, 2024 |
-25.48% |
| Dec 31, 2023 |
59.44% |
| Sep 30, 2023 |
16.31% |
| Jun 30, 2023 |
36.19% |
| Mar 31, 2023 |
-69.45% |
| Dec 31, 2022 |
-50.90% |
| Sep 30, 2022 |
31.19% |
| Jun 30, 2022 |
62.74% |
| Mar 31, 2022 |
6.10% |
| Dec 31, 2021 |
-39.05% |
| Sep 30, 2021 |
27.16% |
| Jun 30, 2021 |
64.42% |
